Welcome to our dedicated page for Yijia Group SEC filings (Ticker: YJGJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Yijia Group Corp. (YJGJ) provides direct access to the company’s regulatory disclosures, with AI-powered tools to help interpret the information. Yijia Group Corp., a Nevada corporation with common stock quoted on the OTC Pink Sheets, uses current reports on Form 8-K to describe material events such as amendments to its Articles of Incorporation, changes in share capital, and corporate rebranding.
In these filings, the company details its name change from Yijia Group Corp. to VitaNova Life Sciences Corporation, including Board and stockholder approvals and the filing of a Certificate of Amendment with the Nevada Secretary of State. The filings also explain a 1-for-3 reverse stock split of its common stock, implemented through the same amendment, and note that FINRA is processing both the name change and the reverse split.
Other important disclosures include increases to the company’s authorized capital stock, authorization of blank check preferred stock, and the filing of a Certificate of Designation that creates Series A Preferred Stock and sets out its powers, preferences, rights, qualifications, limitations and restrictions. The company also reports obtaining a new CUSIP number for its common stock and its intention to change its ticker symbol.
On this page, users can review Yijia Group Corp.’s 8-K filings and related exhibits, while AI-generated summaries highlight the key points in each document. This helps readers quickly understand how amendments, reverse splits, preferred stock designations, and identifier changes affect the company’s capital structure and corporate identity, without needing to parse every technical detail of the underlying forms.
VitaNova Life Sciences Corporation, formerly Yijia Group Corp., reports that its corporate name change and a reverse stock split have now been cleared for trading purposes. The Certificate of Amendment filed in Nevada on January 9, 2026 changed the name to VitaNova Life Sciences Corporation and implemented a 1‑for‑3 reverse stock split, so each stockholder receives one share for every three previously held.
FINRA has completed its review, and both the name change and reverse split take effect on the OTC Pink marketplace as of January 27, 2026. The company’s common stock will trade under the symbol YJGJD for 20 trading days beginning January 27, 2026, after which the ticker will change to VNOV. The company has also obtained a new CUSIP number, 98585W403. The company states that no action is required by current stockholders in relation to these changes.
Yijia Group Corp. is changing its corporate structure and capital setup. The company has filed a Certificate of Amendment in Nevada to change its name to VitaNova Life Sciences Corporation, with the filing effective January 9, 2026, while FINRA processes the name change. In connection with these actions, the company has obtained a new CUSIP number, 98585W403, for its common stock and plans to adopt a new ticker symbol, which it is still evaluating.
The amendment also implements a 1-for-3 reverse stock split, so each stockholder will receive one share of common stock for every three shares held. Earlier, the company increased its authorized capital to 210,000,000 shares, including 200,000,000 common shares and 10,000,000 preferred shares, and designated 3,000,000 of those preferred shares as Series A Preferred Stock with specific rights and preferences approved by the board and majority stockholders.
Yijia Group Corp reported stronger results for the quarter ended October 31, 2025, as its dietary supplement business drove growth. Revenue reached $427,115, up from $292,118, with gross profit of $260,803 and margin improving to 61%. For the first six months, revenue rose to $531,014, a 33% increase, while the net loss narrowed to $10,491 from $22,564 and operating cash flow turned into a $476,471 inflow.
The company ended the quarter with $1,259,281 in cash and total assets of $2,336,244 against $438,051 in current liabilities and no long-term debt. Results are highly concentrated, with a few U.S. customers contributing over 60% of revenue and one vendor providing all purchases, and management continues to disclose material weaknesses in internal controls due to the absence of an independent audit committee.
Yijia Group Corp. plans several major corporate changes. The company intends to change its name to VitaNova Life Sciences Corporation, with a new ticker symbol to follow on OTC Markets; until then, its common stock will continue trading under YJGJ with the current CUSIP.
The board and a majority of common shareholders have approved a reverse stock split in a ratio range of 1-for-2 to 1-for-3, meaning each shareholder would receive one new share for every two or three existing shares once the final ratio is set. They also approved an increase in authorized capital to 85,000,000 shares, consisting of 75,000,000 common and 10,000,000 preferred shares, and the creation of blank check preferred stock that the board can designate into series with different rights over time. These changes will be implemented by filing a Certificate of Amendment with the Nevada Secretary of State after the reverse split ratio is finalized.
YIJIA GROUP CORP. (YJGJ) Q1 Highlights The filing shows total revenue of $108,477 for the period, producing reported gross profit amounts of $68,781 and $73,173 in comparative periods. The company recorded a loss before income tax of $32,440 (and a prior period loss of $45,414). Share capital outstanding totaled 25,012,270 shares. Management applied a full valuation allowance against deferred tax assets, with a net change in that allowance of $17,397. The company reports significant customer and vendor concentrations: one customer ("Customer B") accounted for 100% of revenues amounting to $108,477 and a single vendor represented 54% of purchases ($114,598). Cash balances include material uninsured amounts of $468,926 and $301,267. The company issued share-based compensation arrangements (60,000 shares to the CFO at $0.05 fair value) with common stock issuable of $3,000. Financial statements are unaudited and certain schedules (allowances for credit losses and obsolete inventory) show no recorded reserves.